Mayo Clinic researchers will obtain three whole genome sequences: one from the patients’ healthy cells before treatment and two tumor genomes – one before chemotherapy and one after. Patients will be paired with mouse “avatars” that will help physicians identify the best treatment for each person.
“What is so exciting about this study is that it has the potential to really bring individualized medicine to our patients,” says Matthew Goetz, M.D., Mayo oncologist and study co-leader. “It will transform how we conduct breast cancer research and how drug therapies are delivered to women with breast cancer.”
Click here for entire news release.